icon-folder.gif   Conference Reports for NATAP  
 
  EACS - European AIDS Conference
Oct 12-15 2011
Belgrade, Serbia
Back grey_arrow_rt.gif
 
 
 
Efficacy and viral resistance are comparable when maraviroc is administered once daily or twice daily with boosted protease inhibitors in treatment-experienced patients
 
 
  Reported by Jules Levin EACS 2011 Oct 12-15 Belgrade Serbia
 
Carlo-Federico Perno,1 Charles Craig,2 Steve Taylor,3 José Arribas,4 Robert Burnside,5 David Hardy,6 Hans-Jürgen Stellbrink,7 David A Cooper,8 Jean-Michel Molina,9 Elna van der Ryst,2 Mike Westby,2 Hernan Valdez,10 Jayvant Heera5 1University of Rome, Tor Vergata, Italy; 2Pfizer Global R&D, Sandwich, UK; 3Birmingham Heartlands Hospital, Birmingham, UK; 4Hospital La Paz, Madrid, Spain; 5Pfizer Inc., Groton, CT, USA; 6Cedars-Sinai Medical Center/Geffen School of Medicine-UCLA, Los Angeles, CA, USA; 7ICH Study Center, Hamburg, Germany; 8Kirby Institute, University of New South Wales, Sydney, Australia; 9Assistance Publique-Hopitaux de Paris, Paris, France; 10Pfizer Inc., New York, NY, USA

EACS1.gif

EACS2.gif

EACS3.gif

EACS4.gif

EACS5.gif

EACS6.gif

EACS7.gif

EACS8.gif

EACS9.gif

EACS10.gif

EACS11.gif

References
 
1. Fatkenheuer G, et al. Nat Med 2005; 11: 1170-1172.
2. Gulick RM, et al. N Engl J Med 2008; 359: 1429-1441.
3. Weatherley B et al. Poster 17a presented at the 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA, 7-9 April, 2008.
4. Schapiro JM, et al. Antivir Ther 2011; 16: 395-404.